CN108472275A - 治疗缺血性中风的组合物及方法 - Google Patents

治疗缺血性中风的组合物及方法 Download PDF

Info

Publication number
CN108472275A
CN108472275A CN201680075914.1A CN201680075914A CN108472275A CN 108472275 A CN108472275 A CN 108472275A CN 201680075914 A CN201680075914 A CN 201680075914A CN 108472275 A CN108472275 A CN 108472275A
Authority
CN
China
Prior art keywords
cromolyn
compound
stroke
brain
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680075914.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·埃尔马莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D El Marlay
General Hospital Corp
Original Assignee
Aerts Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerts Treatment Co filed Critical Aerts Treatment Co
Publication of CN108472275A publication Critical patent/CN108472275A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680075914.1A 2015-11-23 2016-11-23 治疗缺血性中风的组合物及方法 Pending CN108472275A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (1)

Publication Number Publication Date
CN108472275A true CN108472275A (zh) 2018-08-31

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680075914.1A Pending CN108472275A (zh) 2015-11-23 2016-11-23 治疗缺血性中风的组合物及方法

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109922800A (zh) * 2016-08-31 2019-06-21 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
HK1223541A1 (zh) 2013-10-22 2017-08-04 The General Hospital Corporation 色甘酸衍生物以及成像和治疗的相关方法
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
AU2017442079A1 (en) * 2017-12-04 2020-06-25 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2019199776A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
IL297023A (en) 2020-04-06 2022-12-01 Massachusetts Gen Hospital Methods for treating inflammatory conditions caused by the corona virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20140140927A1 (en) * 2009-01-29 2014-05-22 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577268A1 (en) * 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
US8617517B2 (en) * 2009-01-29 2013-12-31 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
TW201613969A (en) * 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
US8129404B2 (en) * 2009-03-11 2012-03-06 Plexxikon Inc. Compounds and uses thereof
CN104869993B (zh) * 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
CA2913235C (en) * 2013-05-23 2021-07-13 Aztherapies, Inc. Methods for delivering cromolyn
DK3104853T3 (da) * 2014-02-10 2019-12-09 Respivant Sciences Gmbh Behandling med mastcellestabilisatorer til systemiske forstyrrelser
JP2019524865A (ja) * 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20140140927A1 (en) * 2009-01-29 2014-05-22 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱照静等主编: "《药剂学》", 31 August 2007 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109922800A (zh) * 2016-08-31 2019-06-21 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CN109922800B (zh) * 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞

Also Published As

Publication number Publication date
WO2017091644A1 (en) 2017-06-01
EP3380095B1 (en) 2022-01-05
JP2018538273A (ja) 2018-12-27
KR20180081812A (ko) 2018-07-17
US20180344682A1 (en) 2018-12-06
MX2018006390A (es) 2019-02-14
US20220125753A1 (en) 2022-04-28
MX390748B (es) 2025-03-21
EP3380095A1 (en) 2018-10-03
EP3380095A4 (en) 2019-10-23
CA3005909A1 (en) 2017-06-01
AU2016359674A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
US20220125753A1 (en) Compositions and methods for treating ischemic stroke
US20240058480A1 (en) Cromolyn derivatives and related methods of imaging and treatment
JP2025118787A (ja) 安定なカンナビノイド製剤
US20220054450A1 (en) Stable cannabinoid formulations
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
JPWO2006011397A1 (ja) 糖尿病の予防または治療のための薬剤
CN111840112B (zh) 鼠尾草酸或其衍生物在制备治疗糖尿病并发症药物中的应用
JP6258264B2 (ja) ヒトの血小板レベルを増加させるための組成物および方法
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
US20150320686A1 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
CN120265283A (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
EP4337205A1 (en) Dosing regimens
KR20090024248A (ko) Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
JP2023550407A (ja) 肺高血圧向けの吸入式イマチニブ
JP7257091B2 (ja) 認知症の治療及び予防薬
KR20250173974A (ko) 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물
AU2024279669A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
WO2024249509A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
KR101516452B1 (ko) 관동맥의 묘출능 개선제
Mouihate et al. FINAL ACCEPTED VERSION R-00250-2006. R1
JPS59134722A (ja) 出血性梗塞予防・治療剤
JP2005053890A (ja) アディポネクチン濃度低下及び／又はｃ反応性蛋白濃度上昇及び／又はｉｌ−１８濃度上昇に起因する疾患の予防及び／又は治療剤。
HK1170673B (en) Compositions and methods for increasing blood platelet levels in humans
KR20130038583A (ko) 소포체 스트레스 억제제를 유효성분으로 함유하는 급성 폐 손상의 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210929

Address after: Massachusetts, USA

Applicant after: D El Marlay

Address before: Massachusetts, USA

Applicant before: AZTherapies, Inc.

Effective date of registration: 20210929

Address after: Massachusetts, USA

Applicant after: THE GENERAL Hospital Corp.

Address before: Massachusetts, USA

Applicant before: D El Marlay

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180831

WD01 Invention patent application deemed withdrawn after publication